What is the recommended management and treatment for voltage‑gated potassium channel (VGKC) complex encephalitis?

Management of VGKC Complex Encephalitis

Start high-dose corticosteroids immediately once infection is ruled out, and if no response by the end of the initial treatment cycle, add IVIG or plasma exchange; for refractory cases after 2-4 weeks of combined first-line therapy, escalate to rituximab as second-line treatment. 1

Diagnostic Workup

Before initiating treatment, complete the following essential evaluations:

• Brain MRI and EEG to identify focal or multifocal abnormalities (though MRI may be normal in VGKC encephalitis) 1
• Lumbar puncture to rule out infection and test for oligoclonal bands, IgG index, and neuronal autoantibodies in CSF (note: pleocytosis is uncommon in VGKC encephalitis) 2
• Serum and CSF antibody testing specifically for LGI1 and CASPR2 antibodies, which are the primary antigenic targets in VGKC complex encephalitis 3, 4
• Cancer screening with CT chest/abdomen/pelvis, as thymomas and other malignancies can be associated, particularly with CASPR2 antibodies 1, 5
• Brain FDG-PET if clinical suspicion is high but other studies are uninformative 1

Key Clinical Recognition Points

VGKC complex encephalitis presents distinctively:

• LGI1 antibodies: Limbic encephalitis with memory impairment, disorientation, and faciobrachial dystonic seizures (FBDS) - a pathognomonic feature that responds rapidly to steroids and may prevent progression to full encephalitis 2, 3
• Hyponatremia due to SIADH is extremely common and often a diagnostic clue 3, 5
• CASPR2 antibodies: Morvan's syndrome with insomnia, psychosis, peripheral nerve hyperexcitability, and severe autonomic dysfunction 3, 4

First-Line Immunotherapy

Initial Treatment

High-dose corticosteroids are the preferred first-line agent, particularly for LGI1-associated encephalitis which is notably steroid-responsive 1. The specific regimen:

• Intravenous methylprednisolone 1g daily for 3 days, followed by oral prednisone 1 mg/kg/day 6
• Alternative first-line options if steroids contraindicated: IVIG (2 g/kg) or plasma exchange (5-10 sessions every other day) 1, 6

When to Escalate First-Line Therapy

If no clinical, radiological, or electrophysiological improvement by end of initial treatment cycle 1:

• Add IVIG first in agitated patients or those with bleeding disorders
• Add plasma exchange first in patients with:
  • Severe hyponatremia
  • High thromboembolic risk (cancer, smoking, diabetes, hyperlipidemia)
  • Associated demyelination 1

Combination First-Line Therapy

For severe presentations, consider combined therapy from the beginning rather than sequential treatment 1:

• Steroids + IVIG, or
• Steroids + plasma exchange

One highly effective protocol demonstrated excellent outcomes: plasma exchange (50 ml/kg) + IVIG (2 g/kg) + IV methylprednisolone (1g × 3), followed by maintenance oral prednisolone 6. This regimen achieved seizure remission within 1 week, cognitive improvement within 3 months, and immunological remission (normal VGKC antibody titers) within 1-4 months in all patients 6.

Second-Line Immunotherapy

If no meaningful clinical or radiological response after 2-4 weeks of optimized first-line therapy, initiate second-line agents 1.

Rituximab as Preferred Second-Line

Rituximab is the preferred second-line agent for VGKC complex encephalitis because:

• It is less toxic than cyclophosphamide
• VGKC complex antibodies (LGI1, CASPR2) are antibody-mediated, making B-cell depletion mechanistically appropriate 1
• Cyclophosphamide should be reserved for suspected cell-mediated autoimmunity (classical paraneoplastic syndromes with intracellular antigens) 1

Refractory Cases

If no improvement with conventional second-line therapies, consider novel approaches such as tocilizumab or bortezomib, though evidence is minimal 1.

Maintenance Therapy

Start bridging therapy with 1:

• Gradual oral prednisone taper, or
• Monthly IVIG, or
• Monthly IV methylprednisolone

One case series demonstrated sustained remission 26 months after discontinuing all treatment following the intensive regimen 6.

Critical Pitfalls to Avoid

1. Don't delay treatment waiting for antibody results - start immunotherapy once infection is ruled out if clinical suspicion is high 1
2. Recognize FBDS early - these distinctive seizures are pathognomonic for LGI1 encephalitis and respond rapidly to steroids; early treatment may prevent progression to full encephalitis 2
3. Don't dismiss low-positive VGKC antibody titers in psychiatric presentations - true limbic encephalitis is associated with high antibody titers and specific antigens (LGI1/CASPR2); low-positive titers without neurological symptoms rarely represent true encephalitis 7
4. Monitor for hyponatremia - it's both a diagnostic clue and responds to immunotherapy 5, 6
5. Screen for malignancy, especially with CASPR2 antibodies (thymoma, lung cancer) 5
6. Be aware of plasma exchange complications: bleeding risk, volume shifts (problematic in dysautonomic patients), line-related thrombosis 1

Prognosis

VGKC complex encephalitis has a good prognosis with early aggressive immunotherapy, with most patients showing substantial clinical, cognitive, and radiological improvement 2, 6. Unlike many paraneoplastic encephalitides, VGKC encephalitis is frequently non-paraneoplastic and highly treatment-responsive 2.